PACIRA BIOSCIENCES INC (PCRX) Stock News
NASDAQ:PCRX - Nasdaq - US6951271005 - Common Stock - Currency: USD
PCRX Latest News, Press Relases and Analysis
PACIRA BIOSCIENCES INC (NASDAQ:PCRX), a growth stock which is not overvalued.
Discover PACIRA BIOSCIENCES INC, an undervalued growth gem. NASDAQ:PCRX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Wondering what's happening in today's after-hours session?
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
-- $300 million aggregate share repurchase authorization-- -- Reinforces confidence in 5x30 plan – -- Continued focus on margin expansion and...
KKR acquires German IT firm Datagroup for around $500 million
FRANKFURT (Reuters) -U.S.-based private equity firm KKR has reached a deal with Frankfurt-listed Datagroup to buy the firm in an all-cash transaction that values it at about 450 million euros ($508 million), the IT services provider said on Tuesday. Under the terms of the agreement - the latest in a flurry of acquisitions by the U.S. company - KKR will pay 54 euros for each Datagroup share held, representing a 33% premium on the company's last closing price of 40.75 euros. Shares in Datagroup jumped around 31% on Wednesday on the news, with the stock at its highest since February 2024.
Is Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth?
We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Pacira BioSciences, Inc. (NASDAQ:PCRX) stands against other best pharma stocks to buy for long term growth. U.S. Pharma Turns to China for Drug Deals With big American […]
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative,...
Pacira price target raised to $28 from $25 at Truist
Truist analyst Les Sulewski raised the firm’s price target on Pacira (PCRX) to $28 from $25 and keeps a Hold rating on the shares. The firm cites a settlement with eVenus and counterparts for their generic entry of bupivacaine liposome injectable suspension – gExparel – and now envision peak Exparel sales of $740M by 2029, the analyst tells investors in a research note. The deal also removes the much debated overhang, Truist adds. Published first on TheFly – the ultimate source for real-time, ma
Pacira Biosciences Stock Rises On Patent Litigation Settlement: Retail Sentiment Soars
RBC Capital opined that Pacira's settlement of litigation for generic Exparel, which provides some closure to over a year's worth of overhang and uncertainty for shares, is a win for the company and the Exparel franchise.
Pacira Biosciences Stock Surges After-Hours On Exparel Patent Settlement: Retail Investors Rejoice
As part of the deal, Fresenius is barred from marketing a generic version of Exparel until early 2030.
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
-- Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a confidential...
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals.
PACIRA BIOSCIENCES INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:PCRX showcases decent financial health and profitability, coupled with an attractive price.
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
BRISBANE, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver...
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
-- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the...
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences
Pacira's Stock is Down 76% Over the Last Decade, While the Board and Management Have Enriched Themselves at a Cost of Half a Billion Dollars, Roughly 50% of...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pacira BioSciences, Inc. ("Pacira" or...
Pacira BioSciences, Inc. Class Action: The Gross Law Firm Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of...
Class Action Filed Against Pacira BioSciences, Inc. (PCRX) - March 14, 2025 Deadline to Join - Contact Levi & Korsinsky
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities...
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX)....
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) should contact The Gross Law Firm about pending Class Action - PCRX
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of...
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative,...
The Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming Deadline
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of...